10/17/2017 03:15 p.m. - 04:10 p.m.
Life Sciences and Emerging Companies + Venture Capital
Westin St. Francis Hotel 335 Powell Street San Francisco, CA 94102
Michael J. O'Donnell
When raising a seed round of venture capital, the focus of founders tends toward securing meetings and “acing” their pitches. It is a critical moment in the growth of an early-stage biotech that the first interested party is secured in order to more easily convince other investors to join and complete that round of funding. But what happens when you do succeed in generating interest and commitments for your initial round, and the focus shifts to fundraising new funding rounds? CEOs must then walk the fine line during discussions with the current board regarding new investor capital contributions, dilution rights, criteria for new board members, and the overall, long-term health of the company. The panel of start-up executives, directors, and investors will discuss their perspectives on how to crystalize and close subsequent-stage investment rounds, a complex and unclear path from the outside, but a vital step in the process for founders, while navigating the many personalities and interests involved.
Moderator: Michael J. O’Donnell, Partner, Morrison & Foerster LLP
©1996-2018 Morrison & Foerster LLP. All rights reserved.